UNSPSC 51386102: Paranyline or renytoline

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O2ILF29K8B, chemically known as p-toluamidine, .alpha.-fluoren-9-ylidene-, monohydrochloride but generally known as paranyline, which bears US NIH Compound Identifier 160409. European Medicines Agency schedules Renytoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10278MIG.

The term RENYTOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Paranyline or renytoline bears US NLM identifiers UMLS ID C1882930 and NCI Concept Code C66514. SMILES: C1=CC=C2C(=C1)C3=CC=CC=C3C2=CC4=CC=C(C=C4)C(=N)N.

UNSPSC 51386102 Paranyline or renytoline is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The three recent opportunities posted under this code involve naloxone and drug deactivation systems, a direct-to-manufacturer prescription program RFI, and generic multi-source pharmaceuticals and OTC products — none of which are paranyline or renytoline products. State and local governments do not appear to be actively sourcing paranyline or renytoline as a standalone line item; instead, purchasing offices are tagging broader pharmaceutical, emergency-response, and pharmacy-benefit-program procurements under a code that does not match the actual commodities being acquired. The mismatch between code and solicitation scope suggests either incorrect UNSPSC assignment by issuing bodies or that paranyline and renytoline have minimal or no current demand in state and local government procurement.

The three opportunities reflect activity from Seminole County, Florida (Naloxone & Drug Deactivation Systems, IFB60459723LAS, due July 26, 2023), the Texas Health and Human Services Commission (RFI HHS0017013 for a Direct-to-Manufacturer Prescriptions program, posted April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) in partnership with the Minnesota Department of Administration (Generic Multi-Source Pharmaceuticals and OTC Products RFP S1070000015802, due March 26, 2026). These activities span Florida, Texas, Minnesota, and Oregon but do not represent a coherent procurement pattern for the code's nominal commodity. Unless paranyline or renytoline are ingredients within larger pharmaceutical formulations or emergency-response kits (and not separately line-itemized), this code shows no viable recent purchasing signal for targeted business development.